Replies to post #58820 on Progressive Care Inc (RXMD)

[Wangenstein]

LOSING INTEREST IN AMATEUR ANALYSIS, THAT IS

LOL!!!

RXMD "needs" 859 scripts per day in April? But really needs 1,038 scripts per day in order to "catch up"?

Yeah, good thing RXMD increased YOY revenues by 23% in Q1 to make up for it!

This is why real companies like RXMD don't rely upon amateur analysis with meaningless, arbitrary goals.

Yet again, and as always...

GARBAGE IN, GARBAGE OUT

[Spider Web]

OVER VALUED

Most are obviously selling every chance they can get. Especially when the volume allows. This is reflected in the lack of buyers and the frailing pps. I would never buy at this level. I would not even consider buying until the risk level is diminished to around $0.005. And even then, it would still only be a consideration.

Heavy Dilution through Equity Financing is inevitable here. There is no way out of that. They need it in order to overcome the weak start-up in their Smart Medical Alliance Venture, and MSO Contracts. Because the script growth has topped-out and now showing contraction. It would be smart to just hold off from being inappropriately influenced to buy now. The pps would then take care of itself, by grinding down into the $0.005 area with no problem at all. This would then eliminate "most" downside risk.

And they are not going to Up-Grade soon. That will take much longer, especially after breaking down below 0.01 again. Then, after the Dilutive Equity Finance Package is complete, they can start building towards a small OTC Up-Grade. But this will take another year or so, no doubt. By then, the pps may climb back to $0.02. Then after the Reverse-Split is complete, I would then wait until the pps settles down again before re-evaluating.


JMO